Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vaccinia virus extract, also known as extract of rabbit skin inflamed by vaccinia virus (ERSI), is a complex biological mixture derived from the skin of rabbits inoculated with the vaccinia virus (Lister strain). It contains a variety of active components, including amino acids and nucleic acid-related compounds such as urocanic acid and hypoxanthine. Historically utilized for the treatment of chronic and neuropathic pain, the extract is being investigated for its neuroprotective and anti-inflammatory properties in the context of acute ischemic stroke (AIS). Its mechanism of action involves reducing ischemia-induced cerebral edema, decreasing infarct volume, and scavenging oxygen radicals. Additionally, it has been shown to increase superoxide dismutase (SOD) activity and preserve neuronal viability under hypoxic or hypoglycemic conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on extract of rabbit skin inflamed by vaccinia virus.